- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
Market Overview
The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx%% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
Market segmentation
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market has been segmented into
Eluxadoline
Alosetron
Rifaximin
Loperamide
Diphenoxylate + Atropine
Dicyclomine and Hyoscyamine
By Application, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs has been segmented into:
Hospitals
Clinics
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market.
The report offers in-depth assessment of the growth and other aspects of the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share Analysis
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales, revenue and market share for each player covered in this report.
The major players covered in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs are:
Astellas Pharmaceuticals
GlaxoSmithKline
Actavis
Pfizer
AstraZenenca
Salix Pharmaceuticals Ltd
Among other players domestic and global, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Our analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, with price, sales, revenue and global market share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in 2018 and 2019.
Chapter 3, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Eluxadoline
1.2.3 Alosetron
1.2.4 Rifaximin
1.2.5 Loperamide
1.2.6 Diphenoxylate + Atropine
1.2.7 Dicyclomine and Hyoscyamine
1.3 Market Analysis by Application
1.3.1 Overview: Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Overview of Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market
1.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Astellas Pharmaceuticals
2.1.1 Astellas Pharmaceuticals Details
2.1.2 Astellas Pharmaceuticals Major Business
2.1.3 Astellas Pharmaceuticals SWOT Analysis
2.1.4 Astellas Pharmaceuticals Product and Services
2.1.5 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline SWOT Analysis
2.2.4 GlaxoSmithKline Product and Services
2.2.5 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Actavis
2.3.1 Actavis Details
2.3.2 Actavis Major Business
2.3.3 Actavis SWOT Analysis
2.3.4 Actavis Product and Services
2.3.5 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer SWOT Analysis
2.4.4 Pfizer Product and Services
2.4.5 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 AstraZenenca
2.5.1 AstraZenenca Details
2.5.2 AstraZenenca Major Business
2.5.3 AstraZenenca SWOT Analysis
2.5.4 AstraZenenca Product and Services
2.5.5 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Salix Pharmaceuticals Ltd
2.6.1 Salix Pharmaceuticals Ltd Details
2.6.2 Salix Pharmaceuticals Ltd Major Business
2.6.3 Salix Pharmaceuticals Ltd Product and Services
2.6.4 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer Market Share in 2019
3.3.2 Top 6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by Regions (2015-2020)
4.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Regions (2015-2020)
4.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
4.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
4.5 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Market Share by Country
5.1.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by Country (2015-2020)
5.1.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Country (2015-2020)
5.2 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
5.3 Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
5.4 Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Market Share by Country
6.1.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by Country (2015-2020)
6.1.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Country (2015-2020)
6.2 Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
6.3 UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
6.4 France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
6.5 Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
6.6 Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Regions (2015-2020)
7.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
7.3 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
7.4 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
7.5 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
7.7 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Market Share by Country
8.1.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by Country (2015-2020)
8.1.2 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Country (2015-2020)
8.2 Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
8.3 Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
9.3 Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
9.4 Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
9.5 South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by Type (2015-2020)
10.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Type (2015-2020)
10.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2015-2020)
11 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Segment by Application
11.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2015-2020)
11.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2015-2020)
11.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2015-2020)
12 Market Forecast
12.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Growth Rate (2021-2025)
12.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Regions (2021-2025)
12.2.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025)
12.2.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025)
12.2.3 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025)
12.2.4 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025)
12.2.5 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025)
12.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Type (2021-2025)
12.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Type (2021-2025)
12.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share Forecast by Type (2021-2025)
12.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Application (2021-2025)
12.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Application (2021-2025)
12.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
List of Tables
Table 1. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Growth Estimation in Various Scenarios in 2020
Table 4. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 5. Market Opportunities in Next Few Years
Table 6. Market Risks Analysis
Table 7. Market Drivers
Table 8. Astellas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 9. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Business
Table 10. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Total Revenue (USD Million) (2018-2019)
Table 11. Astellas Pharmaceuticals SWOT Analysis
Table 12. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 13. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 14. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 15. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Business
Table 16. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Total Revenue (USD Million) (2018-2019)
Table 17. GlaxoSmithKline SWOT Analysis
Table 18. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 19. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 20. Actavis Basic Information, Manufacturing Base and Competitors
Table 21. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Business
Table 22. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Total Revenue (USD Million) (2018-2019)
Table 23. Actavis SWOT Analysis
Table 24. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 25. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 26. Pfizer Basic Information, Manufacturing Base and Competitors
Table 27. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Business
Table 28. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Total Revenue (USD Million) (2018-2019)
Table 29. Pfizer SWOT Analysis
Table 30. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 31. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 32. AstraZenenca Basic Information, Manufacturing Base and Competitors
Table 33. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Business
Table 34. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Total Revenue (USD Million) (2018-2019)
Table 35. AstraZenenca SWOT Analysis
Table 36. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 37. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 38. Salix Pharmaceuticals Ltd Basic Information, Manufacturing Base and Competitors
Table 39. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Business
Table 40. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Total Revenue (USD Million) (2018-2019)
Table 41. Salix Pharmaceuticals Ltd SWOT Analysis
Table 42. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 43. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 44. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturer (2018-2019) (K MT)
Table 45. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturer (2018-2019) (USD Million)
Table 46. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Regions (2015-2020) (K MT)
Table 47. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Regions (2015-2020)
Table 48. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Regions (2015-2020) (USD Million)
Table 49. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries (2015-2020) (K MT)
Table 50. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Countries (2015-2020)
Table 51. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries (2015-2020) (USD Million)
Table 52. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries (2015-2020)
Table 53. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries (2015-2020) (K MT)
Table 54. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Countries (2015-2020)
Table 55. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries (2015-2020) (USD Million)
Table 56. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Regions (2015-2020) (K MT)
Table 57. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Regions (2015-2020)
Table 58. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Regions (2015-2020) (USD Million)
Table 59. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries (2015-2020) (K MT)
Table 60. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Countries (2015-2020)
Table 61. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries (2015-2020) (USD Million)
Table 62. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries (2015-2020)
Table 63. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries (2015-2020) (K MT)
Table 64. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Countries (2015-2020)
Table 65. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries (2015-2020) (USD Million)
Table 66. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries (2015-2020)
Table 67. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2015-2020) (K MT)
Table 68. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Type (2015-2020)
Table 69. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2015-2020) (USD Million)
Table 70. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Type (2015-2020)
Table 71. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2015-2020) (K MT)
Table 72. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Application (2015-2020)
Table 73. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Regions (2021-2025) (K MT)
Table 74. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share Forecast by Regions (2021-2025)
Table 75. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Type (2021-2025) (K MT)
Table 76. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share Forecast by Type (2021-2025)
Table 77. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Application (2021-2025)
Table 78. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share Forecast by Application (2021-2025)
Table 79. Direct Channel Pros & Cons
Table 80. Indirect Channel Pros & Cons
Table 81. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Picture
Figure 2. Global Sales Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type in 2019
Figure 3. Eluxadoline Picture
Figure 4. Alosetron Picture
Figure 5. Rifaximin Picture
Figure 6. Loperamide Picture
Figure 7. Diphenoxylate + Atropine Picture
Figure 8. Dicyclomine and Hyoscyamine Picture
Figure 9. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application in 2019
Figure 10. Hospitals Picture
Figure 11. Clinics Picture
Figure 12. Others Picture
Figure 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status and Outlook (2015-2025) (USD Million)
Figure 14. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 18. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 19. UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 22. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 25. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 28. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 31. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 32. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 33. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturer in 2019
Figure 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Manufacturer in 2019
Figure 35. Top 3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer (Revenue) Market Share in 2019
Figure 36. Top 6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer (Revenue) Market Share in 2019
Figure 37. Key Manufacturer Market Share Trend
Figure 38. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 39. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 40. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Regions (2015-2020)
Figure 41. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Regions in 2018
Figure 42. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
Figure 43. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
Figure 44. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
Figure 45. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
Figure 46. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
Figure 47. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 48. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Countries (2015-2020)
Figure 49. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Countries in 2018
Figure 50. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 51. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries in 2018
Figure 52. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 53. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 54. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 55. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 56. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries (2015-2020)
Figure 57. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries in 2019
Figure 58. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 59. UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 60. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 61. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 62. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 63. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 64. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Regions 2019
Figure 65. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Regions 2019
Figure 66. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 67. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 68. Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 69. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 70. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 71. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 72. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Countries in 2019
Figure 73. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries in 2019
Figure 74. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 75. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 76. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 77. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Countries in 2019
Figure 78. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries (2015-2020)
Figure 79. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries in 2019
Figure 80. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 81. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 82. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 83. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 84. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2025) (K MT)
Figure 85. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2021-2025) (USD Million)
Figure 86. North America Sales Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025) (K MT)
Figure 87. Europe Sales Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025) (K MT)
Figure 88. Asia-Pacific Sales Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025) (K MT)
Figure 89. South America Sales Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025) (K MT)
Figure 90. Middle East & Africa Sales Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025) (K MT)
Figure 91. Sales Channel: Direct Channel vs Indirect Channel
Please feel free to write an email to us or to use our electronic ticketing system.
